Australian cancer patients to get improved access to clinical trials

17 March 2022

Australian cancer patients will get improved access to local clinical trials through a new public-private partnership consortium, PrOSPECT, which today announced a funding agreement that is expected to enable a significant increase in local cancer clinical trial participation.

PrOSPECT – Precision Oncology Screening Platform Enabling Clinical Trials – is a collaboration of organisations that has partnered with the federal and NSW governments to expand access to comprehensive genomic profiling for cancer patients and enable clinical trial access.

The local subsidiary of Swiss pharma giant Roche (ROG: SIX), a member of trade group Medicines Australia, is one of the foundational partners of PrOSPECT.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK